Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum

C. Sessa, M. D'Incalci, N. Colombo, G. Pecorelli, C. Mangioni

Research output: Contribution to journalArticle


Twenty-three ovarian cancer patients refractory to first-line chemotherapy consisting of cis-dichlorodiamminoplatinum used as a single agent (50 mg/m2 IV every 4 weeks) were admitted to this study. They received cyclophosphamide as an IV push at a dose of 1 g/m2 every 3 weeks. They were evaluable for response after at least two cycles. None of the 18 evaluable patients responded: 15 (83%) showed rapid progression and three (17%) no change. Except in one case of severe leukopenia hematological toxicity was acceptable. Some (30%) of the patients experienced intractable vomiting on the day of cyclophosphamide administration.

Original languageEnglish
Pages (from-to)33-34
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Issue number1
Publication statusPublished - Aug 1983


ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this